Peanut Allergy

Healio has compiled November’s most read news in asthma and allergy.

An expert at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting addressed the fear surrounding oral food challenges in infants and toddlers and discussed why they should not be deferred.

IgGenix announced the first patient dosed with IGNX001, a monoclonal antibody-based therapeutic for peanut allergy.

SAN ANTONIO — Despite evidence and guidelines, obstacles remain in the prompt introduction of allergenic foods into infant diets, Michael Pistiner, MD, MMSc, told Healio at the 16th Annual Allergy, Asthma & Immunology CME Conference.

Patients infected with SARS-CoV-2 had altered growth patterns in their blood and showed signs of reduced immune cells 10 months after infection, according to a study published in Allergy.

The ADAPT OIT program builds peanut tolerance in babies with daily dosing of peanut powder administered by caregivers at home, according to a National Allergy Centre of Excellence and Murdoch Children’s Research Institute press release.

DBV Technologies recently provided updates on its Viaskin Peanut Program for children and toddlers, announcing recruitment for the VITESSE study and progress in the COMFORT Toddlers supplemental safety study.

The FDA has approved Palforzia, an oral immunotherapy designed to protect children aged 1 to 3 years with peanut allergies from reactions caused by accidental exposure, according to a press release.

The FDA has approved Palforzia for children aged 1 to 3 years who have a peanut allergy that has been diagnosed by a physician, according to a press release from its manufacturer, Stallergenes Greer.

The House Appropriations Committee adopted an amendment that would require the inclusion of peanut-containing products into the Special Supplemental Nutrition Program for Women, Infants, and Children.